Miniatura

Fitxers

PIIS0090825824012204.pdf (951.86 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-01-01

Llicència de publicació

cc-by (c) Mirza, Mansoor R. et al., 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/219582

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.ygyno.2024.12.003

Resum

Purpose. The CDK4/6 inhibitor palbociclib inhibits cyclin A, which is overexpressed in endometrial cancer. Combining palbociclib with endocrine therapy improves efficacy in hormone receptor-positive breast cancer. We investigated palbociclib combined with endocrine therapy for estrogen receptor-positive advanced/recur-rent endometrial cancer. Patients and methods. Thi s placebo-controlled double-blind, randomized phase II screening trial (NCT02730429) enrolled women with measurable/evaluable estrogen receptor-positive endometrioid endome-trial cancer that was primary metastatic or had relapsed after >= 1 prior systemic therapy. Patients were randomized in a 1:1 ratio, stratified by number of prior chemotherapy lines, measurable versus evaluable non- measurable disease, and prior medroxyprogesterone/megestrol acetate treatment, to receive oral letrozole 2.5 mg on days 1-28 plus either oral palbociclib 125 mg or placebo on days 1-21, repeated every 28 days until disease progression or unacceptable toxicity. The primary end point was investigator-assessed progression- free survival (PFS). Results. Among 77 patients randomized between February 16, 2017, and December 21, 2018, 73 were treated (36 with palbociclib-letrozole, 37 with placebo-letrozole). Median follow-up was 21.9 (95 % CI, 16.7 to 22.3) months. Median PFS was 8.3 (95 % CI, 4.6 to 11.2) versus 3.1 (95 % CI, 2.7 to 6.8) months, respectively. In a landmark analysis at 12 months the PFS hazard ratio was 0.57 (95 % CI, 0.32 to 0.99; P = .044). Grade >= 3 adverse events were more common with palbociclib-letrozole (67 %) than placebo-letrozole (30 %), most commonly neutropenia (44 % v 0 %, respectively) . Conclusion. These results support a potential role of the palbociclib-letrozole combination as treatment for hormone receptor-positive advanced/recurrent endometrial cancer. Based on these encouraging results, phase III evaluation of letrozole combined with a CDK4/6 inhibitor is planned. Clinical trial information. NCT02730429 (c) 2024 Published by Elsevier Inc.

Matèries

Càncer d'endometri, Hormonoteràpia

Matèries (anglès)

Endometrial cancer, Hormone therapy

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

MIRZA, Mansoor r., BJØRGE, Line, MARMÉ, Frederik, CHRISTENSEN, René depont, GIL MARTIN, Marta, AURANEN, Annika, ATASEVEN, Beyhan, RUBIO, Maria jesús, SALUTARI, Vanda, LUCZAK, Adam a., RUNNEBAUM, Ingo b., REDONDO, Andrés, LINDEMANN, Kristina, TRILLSCH, Fabian, BARRETINA GINESTA, M. pilar, ROED, Henrik, KURTZ, Jean emmanuel, PETERSSON, Karen s., NYVANG, Gitte bettina, SEHOULI, Jalid. Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial. _Gynecologic Oncology_. 2025. Vol. 192, núm. 128-136. [consulta: 24 de gener de 2026]. ISSN: 0090-8258. [Disponible a: https://hdl.handle.net/2445/219582]

Exportar metadades

JSON - METS

Compartir registre